Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Summer is over and the market moves yesterday made that clear. More on that and the latest news below.

The need-to-know this morning

Wave Life Sciences reported updated results from a mid-stage study of its RNA-editing treatment for the serious lung condition alpha-1 antitrypsin deficiency, or AATD.

Gilead wants to hike price of HIV meds distributed by states

Gilead Sciences is looking to significantly boost the price of several HIV treatments that are distributed by state programs, threatening their financial stability, my colleague Ed Silverman exclusively reports.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page